WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`International Nonproprietary Names for
`Pharmaceutical Substances (INN)
`
`RECOMMENDED International Nonproprietary Names
`(Rec. INN): List 44
`
`Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
`International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
`EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
`Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does
`not imply any recommendation of the use of the substance in medicine or pharmacy.
`Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in
`Cumulative List No. 9, 1996.
`
`Dénominations communes internationales
`des Substances pharmaceutiques (DCI)
`
`Dénominations communes internationales RECOMMANDÉES
`(DCI Rec): Liste 44
`
`Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
`Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org.
`mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous
`sont choisises par l’Organisation mondiale de la Santé en tant que dénominations communes internationales
`recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation
`en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
`On trouvera d’autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–
`35) dans la Liste récapitulative No. 9, 1996.
`
`Denominaciones Comunes Internacionales
`para las Sustancias Farmacéuticas (DCI)
`
`Denominaciones Comunes Internacionales RECOMENDADAS
`(DCI Rec.): Lista 44
`
`De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
`Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
`EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que
`a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas.
`La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone
`recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
`Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran
`reunidas en Cumulative List No. 9, 1996.
`
`183
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 001
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`Proposed INN
`(Latin, English, French, Spanish)
`
`Chemical name or description: Action and use: Molecular formula
`Chemical Abstracts Service (CAS) registry number: Graphic formula
`
`DCI Proposée
`
`DCI Propuesta
`
`adalimumabum
`adalimumab
`
`adalimumab
`
`adalimumab
`
`adrogolidum
`adrogolide
`
`adrogolide
`
`adrogolida
`
`alemcinalum
`alemcinal
`
`alemcinal
`
`184
`
`Nom chimique ou description: Propriétés et indications: Formule brute
`Numéro dans le registre du CAS: Formule développée
`
`Nombre químico o descripción: Acción y uso: Fórmula empírica
`Número de registro del CAS: Fórmula desarrollada
`
`immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human
`tumor necrosis factor), disulfide with human monoclonal D2E7k-chain,
`dimer
`
`immunoglobuline G1, anti-(facteur a de nécrose tumorale humain) (chaîne
`lourde de l’anticorps monoclonal humain D2E7), dimère du disulfure avec la
`chaîne k de l’anticorps monoclonal humain D2E7
`
`inmunoglobulina G1 (anti-factor a de necrosis tumoral humano), dímero del
`disulfuro de la cadena pesada D2E7 monoclonal humana con la cadena k
`D2E7 monoclonal humana
`
`(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[f]thieno[2,3-
`c]quinoline-9,10-diol diacetate (ester)
`
`diacétate de (5aR,11bS)-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno=
`[2,3-c]quinoléine-9,10-diyle
`
`diacetato (éster)de (5aR,11bS)-4,5,5a,6,7,11b-hexahidro-2-propilbenzo=
`[f]tieno[2,3-c]quinolina-9,10-dilo
`
`C22H25NO4S
`
`H3C
`
`H3C
`
`O
`
`O
`
`O
`
`O
`
`H3C
`
`S
`
`H
`
`NH
`H
`
`8,9-didehydro-N-demethyl-9-deoxo-4'’,6,12-trideoxy-6,9-epoxy-
`N-ethylerythromycin
`
`(2R,3S,4R,5R,8R,9S,10S,11R,12R)-5-éthyl-11-[[3-(éthylméthylamino)-
`3,4,6-tridésoxy-b-D-xylo-hexopyranosyl]oxy]-3-hydroxy-
`2,4,8,10,12,14-hexaméthyl-9-[(3-C-méthyl-3-O-méthyl-2,4,6-tridésoxy-
`a-L-erythro-hexopyranosyl)oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-
`én-7-one
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 002
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`alemcinal
`
`8,9-dideshidro-N-desmetil-9-desoxo-4'’,6,12-tridesoxi-6,9-epoxi-
`N-etileritromicina
`
`C38H67NO10
`
`H3C
`
`H3C
`
`CH3
`
`H3C
`
`N
`
`O
`
`O
`CH3
`
`OH
`
`H
`O
`
`H
`
`O
`
`CH3
`OCH3
`
`CH3
`H
`H
`
`O
`HO
`H
`CH3
`O
`H
`
`O
`
`H CH3
`
`CH3
`H
`
`CH3
`
`CH3
`
`(-)-5-ethynylnicotine
`
`(-)-3-éthynyl-5-[(2S)-1-méthylpyrrolidin-2-yl]pyridine
`
`(-)-5-etinilnicotina
`
`C12H14N2
`
`N
`
`NC
`
`H3
`
`H
`
`CH
`
`(R)-4-(2-naphthamido)-N,N-dipentylglutaramic acid
`
`acide (4R)-5-(dipentylamino)-4-[(naphtalén-2-ylcarbonyl)amino]-
`5-oxopentanoïque
`
`altiniclinum
`altinicline
`
`altinicline
`
`altiniclina
`
`amiglumidum
`amiglumide
`
`amiglumide
`
`185
`
`amiglumida
`
`(R)-4-(2-naftamido)-N,N-dipentilglutarámico
`
`C26H36N2O4
`
`CH3
`
`CH3
`
`CO2H
`
`N
`
`O
`
`HO
`
`NH
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 003
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`[(6-guanidinohexyl)carbamoyl]methyl [4-[[(R)-3-aminobutyl]amino]butyl]=
`carbamate
`
`[4-[[(3R)-3-aminobutyl]amino]butyl]carbamate de
`2-[(6-guanidinohexyl)amino]-2-oxoéthyle
`
`[4-[[(R)-3-aminobutil]amino]butil]carbamato de
`[(6-guanidinohexil)carbamoil]metilo
`
`NH2
`
`H CH3
`
`HN
`
`O
`
`NH
`
`O
`
`O
`
`HN
`
`C18H39N7O3
`
`NH
`
`NH
`
`H2N
`
`1-ethyl-3-(methylamino)-2(1H)-quinoxalinone
`
`1-éthyl-3-(méthylamino)quinoxalin-2(1H)-one
`
`1-etil-3-(metilamino)-2(1H)-quinoxalinona
`
`C11H13N3O
`
`CH3
`
`HN
`
`O
`
`N
`
`H3C
`
`N
`
`ethyl (±)-4'-[[a-(p-fluorophenyl)-a,4-dihydroxy-m-tolyl]oxy]-
`3',5'-dimethyloxanilate
`
`[[4-[3-[(RS)-(4-fluorophényl)hydroxyméthyl]-4-hydroxyphénoxy]-
`3,5-diméthylphényl]amino]oxoacétate d'éthyle
`
`(±)-4'-[[a-(p-fluorofenil)-a,4-dihidroxi-m-tolil]oxi]-3',5'-dimetiloxanilato de etilo
`
`O
`
`CH3
`
`and enantiomer
`et énantiomère
`y enantiómero
`
`O
`
`O
`
`HN
`
`H3C
`
`O
`
`C25H24FNO6
`
`F
`
`HO
`
`H OH
`
`CH3
`
`anisperimusum
`anisperimus
`
`anispérimus
`
`anisperimus
`
`ataquimastum
`ataquimast
`
`ataquimast
`
`ataquimast
`
`axitiromum
`axitirome
`
`axitirome
`
`axitiromo
`
`186
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 004
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`bilastinum
`bilastine
`
`bilastine
`
`bilastina
`
`binetrakinum
`binetrakin
`
`binétrakine
`
`binetrakina
`
`cangrelorum
`cangrelor
`
`cangrélor
`
`cangrelor
`
`p-[2-[4-[1-(2-ethoxyethyl)-2-benzimidazolyl]piperidino]ethyl]-
`a-methylhydratropic acid
`
`acide 2-[4-[2-[4-[1-(2-éthoxyéthyl)-1H-benzimidazol-2-yl]pipéridin-
`1-yl]éthyl]phényl]-2-méthylpropanoïque
`
`ácido p-[2-[4-[1-(2-etoxietil)-2-bencimidazolil]piperidino]etil]-
`a-metilhidratrópico
`
`H3C
`
`CH3
`
`CO2H
`
`C28H37N3O3
`
`O
`
`H3C
`
`N
`
`N
`
`N
`
`interleukin 4 (human)
`
`interleukine 4 humaine
`
`interleuquina 4 (humana)
`
`HKCDITLQEI IKTLNSLTEQ KTLCTELTVT DIFAASKNTT
`
`EKETFCRAAT VLRQFYSHHE KDTRCLGATA
`
`QQFHRHKQLI
`
`RFLKRLDRNL WGLAGLNSCP VKEANQSTLE NFLERLKTIM
`
`REKYSKCSS
`
`N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid,
`monoanhydride with (dichloromethylene)diphosphonic acid
`
`monoanhydride dichlorométhylènediphosphonique N-[2-(méthylsulfanyl)
`éthyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]-5’-adénylique
`
`monoanhidrido del ácido N-[2-(metiltio)etil]-2-[(3,3,3-trifluoropropil)tio]-
`5'-adenílico con ácido (diclorometileno)difosfónico
`
`187
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 005
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`C17H25Cl2F3N5O12P3S2
`
`NN
`
`NH
`
`N
`
`S
`
`N
`
`S
`
`H3C
`
`F3C
`Cl
`
`O
`
`P
`HO O
`
`O
`
`P
`O OH
`
`O
`
`OH
`
`OH
`
`HO
`HO
`
`Cl
`
`P
`O
`
`cetuximabum
`cetuximab
`
`cétuximab
`
`cetuximab
`
`cilomilastum
`cilomilast
`
`cilomilast
`
`cilomilast
`
`conivaptanum
`conivaptan
`
`conivaptan
`
`conivaptán
`
`188
`
`immunoglobulin G 1 (human-mouse monoclonal C225 g1-chain anti-human
`epidermal growth factor receptor), disulfide with human-mouse monoclonal
`C225 k-chain, dimer
`
`immunoglobuline G1, anti-(récepteur du facteur de croissance humain de
`l’épiderme) (chaîne g1 de l’anticorps monoclonal chimérique homme-souris
`C225), dimère du disulfure avec la chaîne k de l’anticorps monoclonal
`chimérique homme-souris C225
`
`inmunoglobulina G 1, anti-(receptor del factor humano de crecimiento de la
`epidermis)(cadena g1-del anticuerpo monoclonal quimérico hombre-ratón
`C225), dímero del disulfuro con la cadena k del anticuerpo monoclonal
`quimérico hombre-ratón C225
`
`cis-4-cyano-4-[3-(cyclopentyloxy)-4-
`methoxyphenyl]cyclohexanecarboxylic acid
`
`acide cis-4-cyano-4-[3-(cyclopentyloxy)-
`4-méthoxyphényl]cyclohexanecarboxylique
`
`ácido cis-4-ciano-4-[3-(ciclopentiloxi)-4-metoxifenil]ciclohexanocarboxílico
`
`C20H25NO4
`
`H3CO
`
`O
`
`CO2H
`H
`
`NC
`
`4'’-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]-
`2-biphenylcarboxanilide
`
`N-[4-[(2-méthyl-4,5-dihydroimidazo[4,5-d][1]benzaépin-6(1H)-
`yl)carbonyl]phényl]biphényle-2-carboxamide
`
`4'’-[(4,5-dihidro-2-metilimidazo[4,5-d][1]benzazepin-6(1H)-il)carbonil]-
`2-bifenilcarboxanilida
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 006
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`C32H26N4O2
`
`NH
`
`N
`
`CH3
`
`O
`
`N
`
`NH
`
`O
`
`(2R,6S)-3-[(2S)-2-(benzyloxy)propyl]-1,2,3,4,5,6-hexahydro-6,11,11-
`trimethyl-2,6-methano-3-benzazocin-10-ol
`
`(2R,6S)-3-[(2S)-2-(benzyloxy)propyl]-6,11,11-triméthyl-1,2,3,4,5,6-
`hexahydro-2,6-méthano-3-benzazocin-10-ol
`
`(2R,6S)-3-[(2S)-2-(benciloxi)propil]-1,2,3,4,5,6-hexahidro-6,11,11-trimetil-
`2,6-metano-3-benzazocin-10-ol
`
`C25H33NO2
`
`OH
`
`H
`
`N
`CH3
`CH3
`
`O
`
`H CH3
`
`CH3
`
`L-cystine
`
`L-cystine
`
`L-cistina
`
`C6H12N2O4S2
`
`HO2C
`
`S
`
`S
`
`H NH2
`
`H
`
`NH2
`
`CO2H
`
`(+)-(S)-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-methoxy-3,3-
`diphenylpropionic acid
`
`(+)-acide (2S)-2-(4,6-diméthoxypyrimidin-2-yloxy)-3-méthoxy-
`3,3-diphénylpropanoïque
`
`ácido (+)-(S)-2-[(4,6-dimetoxi-2-pirimidinil)oxi]-3-metoxi-3,3-difenilpropiónico
`
`189
`
`crobenetinum
`crobenetine
`
`crobénétine
`
`crobenetina
`
`cystinum
`cystine
`
`cystine
`
`cistina
`
`darusentanum
`darusentan
`
`darusentan
`
`darusentán
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 007
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`C22H22N2O6
`
`OCH3
`
`OCH3
`
`NN
`
`CO2H
`H
`
`O
`
`H3CO
`
`donitriptanum
`donitriptan
`
`donitriptan
`
`1-[[[3-(2-aminoethyl)indol-5-yl]oxy]acetyl]-4-(p-cyanophenyl)piperazine
`
`1-[2-[[3-(2-aminoéthyl)-1H-indol-5-yl]oxy]acétyl]-4-(4-
`cyanophényl)pipérazine
`
`donitriptán
`
`1-[[[3-(2-aminoetil)indol-5-il]oxi]acetil]-4-(p-cianofenil)piperazina
`
`NH2
`
`HN
`
`N
`
`N
`
`O
`
`O
`
`C23H25N5O2
`
`NC
`
`doxercalciferolum
`doxercalciferol
`
`doxercalciférol
`
`doxercalciferol
`
`(5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1a,3b-diol
`(5Z,7E,22E)-9,10-sécoergosta-5,7,10(19),22-tétraène-1a,3b-diol
`
`(5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraeno-1a,3b-diol
`
`C28H44O2
`
`H3C
`CH3
`
`H
`
`H
`
`H
`
`CH3
`
`CH3
`
`H3C
`
`H
`
`CH2
`
`OH
`
`H
`
`HO
`
`H
`
`leukemia-inhibiting factor (human)
`
`facteur d’inhibition leucémique humain
`
`factor inhibidor de leucemia (humano)
`
`emfilerminum
`emfilermin
`
`emfilermine
`
`emfilermina
`
`190
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 008
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`SPLPITPVNA
`
`TCAIRHPCHN
`
`NLMNQIRSQL
`
`AQLNGSANAL
`
`FILYYTAQGE
`
`PFPNNLDKLC
`
`GPNVTDFPPF
`
`HANGTEKAKL
`
`VELYRIVVYL
`
`GTSLGNITRD
`
`QKILNPSALS
`
`LHSKLNATAD
`
`ILRGLLSNVL
`
`CRLCSKYHVG
`
`HVDVTYGPDT
`
`SGKDVFQKKK
`
`LGCQLLGKYK
`
`QIIAVLAQAF
`
`6-benzyl-1-(ethoxymethyl)-5-isopropyluracil
`
`6-benzyl-1-(éthoxyméthyl)-5-(1-méthyléthyl)pyrimidine-2,4(1H,3H)-dione
`
`6-bencil-1-(etoximetil)-5-isopropiluracilo
`
`C17H22N2O3
`
`O
`
`CH3
`
`HN
`
`CH3
`
`O
`
`N
`
`H3C
`
`O
`
`9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-
`methylenecyclopentyl]guanine
`
`2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxyméthyl)-
`2-méthylènecyclopentyl]-1,9-dihydro-6H-purin-6-one
`
`9-[(1S,3R,4S)-4-hidroxi-3-(hidroximetil)-2-metilenociclopentil]guanina
`
`CH2
`
`H
`
`OH
`
`H OH
`
`C12H15N5O3
`
`NN
`
`H
`
`O
`
`N
`
`HN
`
`H2N
`
`mouse IgG 1 monoclonal antibody which binds the human muc-1 gene
`product
`immunoglobuline G2a, anti-(antigène CD20 humain) (chaîne g2a de
`l’anticorps monoclonal de souris B1R1), dimère du disulfure avec la chaîne
`l de l’anticorps monoclonal de souris B1R1
`
`191
`
`emivirinum
`emivirine
`
`émivirine
`
`emivirina
`
`entecavirum
`entecavir
`
`entécavir
`
`entecavir
`
`epitumomabum
`epitumomab
`
`épitumomab
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 009
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`epitumomab
`
`epratuzumabum
`epratuzumab
`
`épratuzumab
`
`epratuzumab
`
`eptapironum
`eptapirone
`
`eptapirone
`
`eptapirona
`
`inmunoglobulina G2a, anti-(antígeno CD20 humano) (cadena g2a del
`anticuerpo monoclonal de ratón B1R1), dímero del disulfuro con la cadena l
`del anticuerpo monoclonal de ratón B1R1
`
`immunoglobulin G (human-mouse monoclonal IMMU-hLL2 g-chain
`anti-human antigen CD22), disulfide with human-mouse monoclonal
`IMMU-hLL2 k-chain, dimer
`immunoglobuline G, anti-(antigène CD22 humain) (chaîne g de l’anticorps
`monoclonal de souris IMMU-hLL2 humanisé), dimère du disulfure avec la
`chaîne k de l’anticorps monoclonal de souris IMMU-hLL2 humanisé
`
`inmunoglobulina G, anti-(antígeno CD22 humano)(cadena g del anticuerpo
`monoclonal humanizado de ratón IMMU-hLL2) dímero del disulfuro con la
`cadena k del anticuerpo monoclonal humanizado de ratón IMMU-hLL2
`
`4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-as-triazine-3,5(2H,4H)-
`dione
`
`4-méthyl-2-[4-[4-(pyrimidin-2-yl)pipérazin-1-yl]butyl]-1,2,4-triazine-3,5(2H,4H)-
`dione
`
`4-metil-2-[4-[4-(2-pirimidinil)-1-piperazinil]butil]-as-triazina-3,5(2H,4H)-diona
`
`C16H23N7O2
`
`O
`
`N
`
`H3C
`
`N
`N
`
`O
`
`N
`
`N
`
`N
`
`N
`
`escitalopramum
`escitalopram
`
`escitalopram
`
`(+)-(S)-1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile
`
`(+)-(1S)-1-[3-(diméthylamino)propyl]-1-(4-fluorophényl)-
`1,3-dihydroisobenzofurane-5-carbonitrile
`
`escitalopram
`
`(+)-(S)-1-[3-(dimetilamino)propil]-1-(p-fluorofenil)-5-ftalancarbonitrilo
`
`C20H21FN2O
`
`F
`
`CH3
`
`N
`CH3
`
`O
`
`NC
`
`192
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0010
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`evernimicinum
`evernimicin
`
`évernimicine
`
`evernimicina
`
`O-(1R)-2,3-O-methylene-4-O-(6-methyl-b-resorcyloyl)-D-xylopyranosylidene-(1
`3-4)-a-L-lyxopyranosyl O-2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-a-L-
`arabino-hexopyranosyl-(1®3)-O-2,6-dideoxy-4-O-(3,5-dichloro-6-methoxy-4,2-
`cresotoyl)-b-D-arabino-hexopyranosyl-(1®4)-O-(1R)-2,6-dideoxy-D-arabino-
`hexopyranosylidene-(1®3-4)-O-6-deoxy-3-C-methyl-b-D-mannopyranosyl-
`(1®3)-O-6-deoxy-4-O-methyl-b-D-galactopyranosyl-(1®4)-2,6-di-O-methyl-b-D-
`mannopyranoside
`
`O-3-C-méthyl-4-O-méthyl-3-nitro-2,3,6-tridésoxy-a-L-arabino-hexopyranosyl-
`(1®3)-O-4-O-(3,5-dichloro-4-hydroxy-2-méthoxy-6-méthylbenzoyl)-2,6-
`didésoxy-b-D-arabino-hexopyranosyl-(1®4)-O-(1R)-2,6-didésoxy-D-arabino-
`hexopyranosylidène-(1®3-4)-O-3-C-méthyl-6-désoxy-b-D-mannopyranosyl-
`(1®3)-O-4-O-méthyl-6-désoxy-b-D-galactopyranosyl-(1®4)-2,6-di-O-méthyl-b-
`D-mannopyranoside de O-(1R)-4-O-(2,4-dihydroxy-6-méthylbenzoyl)-2,3-O-
`méthylène-D-xylopyranosylidène-(1®3-4)-a-L-lyxopyranosyle
`
`O-2,3,6-tridesoxi-3-C-metil-4-O-metil-3-nitro-a-L-arabino-hexopiranosil-(1®3)-
`O-2,6-didesoxi-4-O-(3,5-dicloro-6-metoxi-4,2-cresotoil)-b-D-arabino-
`hexopiranosil-(1®4)-O-(1R)-2,6-didesoxi-D-arabino-hexopiranosilideno-
`(1®3-4)-O-6-desoxi-3-C-metil-b-D-manopiranosil-(1®3)-O-6-desoxi-
`4-O-metil-b-D-galactopiranosil-(1®3)-2,6-di-O-metil-b-D-manopiranósido de O-
`(1R)-2,3-O-metileno-4-O-(6-metil-b-resorciloil)-D-xilopiranosilideno-
`(1®3-4)-a-L-lixopiranosilo
`
`C70H97Cl2NO38
`
`O
`
`O
`
`O
`
`HO
`
`O
`
`CH3
`
`O
`
`O
`
`OH
`
`O
`
`O
`
`H3C
`
`OH
`
`O
`O
`
`193
`
`O
`O
`
`OH
`
`CH3
`
`O
`
`O
`
`OC
`
`H3
`
`O
`
`OH
`
`H3C
`H3
`
`O
`HO
`
`OC
`
`CH3
`
`CH3
`
`OH
`
`O
`
`O
`
`H3C
`
`O
`
`CH3
`
`O
`
`O
`
`O
`
`O
`
`CH3
`CH3
`
`O
`
`O
`
`H3C
`
`NO2
`
`OCH3
`
`Cl
`
`Cl
`
`OH
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0011
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
`9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-
`9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-
`3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-
`6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]=
`oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
`
`(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-
`dihydroxy-12-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyéthoxy)-3-
`méthoxycyclohexyl]-1-méthyléthyl]-19,30-diméthoxy-15,17,21,23,29,35-
`hexaméthyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-
`16,24,26,28-tétraène-2,3,10,14,20-pentone
`
`(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
`9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahidro-
`9,27-dihidroxi-3-[(1R)-2-[(1S,3R,4R)-4-(2-hidroxietoxi)-3-metoxiciclohexil]-
`1-metiletil]-10,21-dimetoxi-6,8,12,14,20,26-hexametil-23,27-epoxi-
`3H-pirido[2,1-c][1,4]oxaazaciclohentriacontina-1,5,11,28,29(4H,6H,31H)-
`pentona
`
`OH
`
`H
`
`CH3
`O
`H
`
`H
`
`OH
`
`O
`
`H
`H3C H
`CH3
`CH3
`
`OCH3
`H3C
`
`H
`
`H
`
`H
`O
`
`H OCH3
`
`CH3
`
`H
`
`C53H83NO14
`
`O
`
`H
`
`H
`H3CO
`
`H
`O
`
`O O
`
`H
`
`O
`
`H
`
`N O H
`
`3C
`
`(2S,3S)-2-(diphenylmethyl)-3-[(5-isopropyl-2-methoxybenzyl)amino]=
`quinuclidine
`
`(2S,3S)-2-(diphénylméthyl)-N-[2-méthoxy-5-(1-méthyléthyl)benzyl]-
`1-azabibyclo[2.2.2]octan-3-amine
`
`(2S,3S)-2-(difenilmetil)-3-[(5-isopropil-2-metoxibencil)amino]quinuclidina
`
`everolimusum
`everolimus
`
`évérolimus
`
`everolimus
`
`ezlopitantum
`ezlopitant
`
`ezlopitant
`
`ezlopitant
`
`194
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0012
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`C31H38N2O
`
`CH3
`
`CH3
`
`H3CO
`
`HN
`
`H H
`
`N
`
`8-phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano=
`[3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-
`2,4(1H,3H)-dione
`
`3-[4-[(3aR,9bR)-9-méthoxy-1,3a,4,9b-tétrahydro[1]benzopyrano[3,4-
`c]pyrrol-2(3H)-yl]butyl]-8-phénylpyrazino[2',3':4,5]thiéno[3,2-d]pyrimidine-
`2,4(1H,3H)-dione
`
`8-fenil-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahidro-9-metoxi[1]benzopirano[3,4-c]=
`pirrol-2(3H)-il]butil]pirazino[2',3':4,5]tieno[3,2-d]pirimidina-2,4(1H,3H)-diona
`
`C30H29N5O4S
`
`OCH3
`H
`
`N
`
`O
`
`H
`
`N
`
`S
`
`O
`
`N
`
`N
`
`NH
`
`O
`
`(S)-N-[bis(3,5-trifluoromethyl)phenethyl]-4-(cyclopropylmethyl)-N-methyl-
`a-phenyl-1-piperazineacetamide
`
`(2S)-N-[2-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-[4-(cyclopropylméthyl)=
`pipérazin-1-yl]-N-méthyl-2-phénylacétamide
`
`(S)-N-[bis(3,5-trifluorometil)fenetil]-4-(ciclopropilmetil)-N-metil-a-fenil-
`1-piperazinaacetamida
`
`C27H31F6N3O
`
`N
`
`O
`
`N
`
`N
`H CH3
`
`CF3
`
`CF3
`
`195
`
`fiduxosinum
`fiduxosin
`
`fiduxosine
`
`fiduxosina
`
`figopitantum
`figopitant
`
`figopitant
`
`figopitant
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0013
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`(aS)-a-[a-(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)-p-tolyl]-
`N-[(aR)-a-(hydroxymethyl)benzyl]cyclopentaneacetamide
`
`(2S)-2-cyclopentyl-2-[4-[(2,4-diméthyl-9H-pyrido[2,3-b]indol-
`9-yl)méthyl]phényl]-N-[(1R)-2-hydroxy-1-phényléthyl]acétamide
`
`(aS)-a-[a-(2,4-dimetil-9H-pirido[2,3-b]indol-9-il)-p-tolil]-
`N-[(aR)-a-(hidroximetil)bencil]ciclopentanoacetamida
`
`OH
`
`O
`
`H
`
`NH
`
`H
`
`C35H37N3O2
`
`N
`
`N
`
`CH3
`
`H3C
`
`5-[o-[2-(dimethylamino)ethoxy]phenyl]-3-phenyl-1,2,4-oxadiazole
`
`N,N-diméthyl-2-[2-(3-phényl-1,2,4-oxadiazol-5-yl)phénoxy]éthanamine
`
`5-[o-[2-(dimetilamino)etoxi]fenil]-3-fenil-1,2,4-oxadiazol
`
`C18H19N3O2
`
`NC
`
`H3
`
`H3C
`
`O
`
`NO
`
`N
`
`(R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-
`1,5'-[5H]inden]-7'(6'H)-one
`
`(6’R)-6’-hydroxy-3’-(hydroxyméthyl)-2’,4’,6’-triméthylspiro[cyclopropane-
`1,5’-[5H]indén]-7’(6’H)-one
`
`(R)-6'-hidroxi-3'-(hidroximetil)-2',4',6'-trimetilspiro[ciclopropano-
`1,5'-[5H]inden]-7'(6'H)-ona
`
`implitapidum
`implitapide
`
`implitapide
`
`implitapida
`
`irampanelum
`irampanel
`
`irampanel
`
`irampanel
`
`irofulvenum
`irofulven
`
`irofulvène
`
`irofulveno
`
`196
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0014
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`itriglumidum
`itriglumide
`
`itriglumide
`
`itriglumida
`
`laniceminum
`lanicemine
`
`lanicémine
`
`lanicemina
`
`lusaperidonum
`lusaperidone
`
`lusapéridone
`
`lusaperidona
`
`C15H18O3
`
`O
`
`HO
`H3C
`
`CH3
`
`CH3
`
`OH
`
`(R)-2'-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4',6'-dimethyl-
`3-(1-naphthyl)glutaranilic acid
`
`acide (3R)-5-[[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-
`diméthylphényl]amino]-3-(naphtalén-1-yl)-5-oxopentanoïque
`
`ácido (R)-2'-(8-azaspiro[4.5]dec-8-ilcarbonil)-4',6'-dimetil-
`3-(1-naftil)glutaranílico
`
`C33H38N2O4
`
`CO2H
`H
`
`O
`
`H3C
`
`NH O
`
`N
`
`CH3
`
`(+)-2-[(S)-b-aminophenethyl]pyridine
`
`(+)-(1S)-1-phényl-2-(pyridin-2-yl)éthanamine
`
`(+)-2-[(S)-b-aminofenetil]piridina
`
`C13H14N2
`
`N
`
`H NH2
`
`3-[2-(3,4-dihydrobenzofuro[3,2-c]pyridin-2(1H)-yl)ethyl]-2-methyl-
`4H-pyrido[1,2-a]pyrimidin-4-one
`
`3-[2-(3,4-dihydrobenzofuro[3,2-c]pyridin-2(1H)-yl)éthyl]-2-méthyl-4H-
`pyrido[1,2-a]pyrimidin-4-one
`
`3-[2-(3,4-dihidrobenzofuro[3,2-c]piridin-2(1H)-il)etil]-2-metil-
`4H-pirido[1,2-a]pirimidin-4-ona
`
`197
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0015
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`C22H21N3O2
`
`N
`
`CH3
`
`N
`
`O
`
`N
`
`O
`
`N-methionylleptin (human)
`
`N-méthionylleptine humaine
`
`N-metionileptina (humana)
`
`C714H1167N191O221S6
`
`M
`
`VPIQKVQDDT
`
`KTLIKTIVTR
`
`INDISHTQSV
`
`SSKQKVTGLD
`
`FIPGLHPILT
`
`LSKMDQTLAV
`
`YQQILTSMPS
`
`RNVIQISNDL
`
`ENLRDLLHVL
`
`AFSKSCHLPW
`
`ASGLETLDSL
`
`GGVLEASGYS
`
`TEVVALSRLQ
`
`GSLQDMLWQL
`
`DLSPGC
`
`immunoglobulin G2b (mouse monoclonal BEC2 g2b-chain anti-GD3
`ganglioside), disulfide with mouse monoclonal BEC2 k-chain, dimer
`
`immunoglobuline G2b, anti-(ganglioside GD3) (chaîne g2b de l’anticorps
`monoclonal de souris BEC2), dimère du disulfure avec la chaîne k de
`l’anticorps monoclonal de souris BEC2
`
`inmunoglobulina G2b,anti-(gangliósido GD3)(cadena g2b del anticuerpo
`monoclonal de ratón BEC2) dímero del disulfuro con la cadena k del
`anticuerpo monoclonal de ratón BEC2
`
`9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-
`dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-
`dipropanol
`
`3,3'-[9,10-diéthyl-20,21-bis[2-[2-(2-méthoxyéthoxy)éthoxy]éthoxy]-
`4,15-diméthyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloicosène-
`5,14-diyl]dipropan-1-ol
`
`9,10-dietil-20,21-bis[2-[2-(2-metoxietoxi)etoxi]etoxi]-4,15-dimetil-8,11-imino-
`3,6:16,13-dinitrilo-1,18-benzodiazacicloeicosina-5,14-dipropanol
`
`metreleptinum
`metreleptin
`
`métréleptine
`
`metreleptina
`
`mitumomabum
`mitumomab
`
`mitumomab
`
`mitumomab
`
`motexafinum
`motexafin
`
`motéxafine
`
`motexafina
`
`198
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0016
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`H3C
`
`OH
`
`CH3
`
`CH3
`
`N
`
`N
`
`HN
`
`NN
`
`H3C
`
`OH
`
`C48H67N5O10
`
`H3C
`
`H3C
`
`O
`O
`
`O
`
`O
`
`O
`O
`
`O
`
`O
`
`(S)-4-amino-N-(4,4-dimethylcyclohexyl)glutaramic acid
`
`acide (4S)-4-amino-5-[(4,4-diméthylcyclohexyl)amino]-5-oxopentanoïque
`
`ácido (S)-4-amino-N-(4,4-dimetilciclohexil)glutarámico
`
`CH3
`CH3
`
`C13H24N2O3
`
`HN
`
`H
`
`NH2
`
`O
`
`HO2C
`
`glycoprotein TNF-BP (tumor necrosis factor-binding protein) (human
`disulfide variant 1)
`
`20-180-récepteur 1 humain du facteur de nécrose tumorale, protéine
`glycosylée (partie du domaine extracellulaire)
`
`glicoproteína TNF-BP (proteína de unión al factor de necrosis
`tumoral)(disulfuro de la variante 1 humana)
`
`C753H1156N228O247S25
`
`DSVCPQGKYI
`
`*
`HPQNNSICCT
`
`KCHKGTYLYN
`
`DCPGPGQDTD
`
`CRECESGSFT
`
`ASENHLRHCL
`
`SCSKCRKEMG
`
`QVEISSCTVD
`
`RDTVCGCRKN
`
`QYRHYWSENL
`
`*
`FQCFNCSLCL
`
`*
`NGTVHLSCQE
`
`
`
`KQNTVCTCHA
`N
`
`GFFLRENECV
`
`SCSNCKKSLE
`
`CTKLCLPQIE
`
`* glycosylation sites
`* sites de glycosylation
`* posiciónes de glicosilación
`
`199
`
`nebostinelum
`nebostinel
`
`nébostinel
`
`nebostinel
`
`onerceptum
`onercept
`
`onercept
`
`onercept
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0017
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`18-L-aspartic acid-21-L-asparagine-120-L-lysine-167-L-asparagine-
`168-L-alanine-171-L-serine-172-L-arginine-174-L-serine-179-L-threonine
`growth hormone (human), reaction product with polyethylene glycol
`
`[18-acide L-aspartique-21-L-asparagine-120-L-lysine-167-L-asparagine
`-168-L-alanine-171-L-sérine-172-L-arginine-174-L-sérine-179-L-thréonine]
`hormone humaine de croissance combinée à du polyéthylène glycol
`
`producto de reacción con polietilenglicol de la 18-ácido-L-aspártico
`21-L-asparagina-120-L-lisina-167-L-asparagina-168-L-alanina-171-L-serina-
`172-L-arginina-174-L-serina-179-L-treoninahormona del crecimiento
`(humana)
`
`KYSFLQNPQT SLCFSESIPT
`
`*
`FPTIPLSRLF DNAMLRADRL NQLAFDTYQE FEEAYIPKEQ
`*
`PSNREETQQK SNLELLRISL
`*
`LLIQSWLEPV QFLRSVFANS LVYGASDSNV YDLLKDLEEK
`*
`*
`*
`GSPRTGQIFK QTYSKFDTNS HNDDALLKNY
`
`IQTLMGRLED
`
`GLLYCFNADM SRVSTFLRTV
`
`QCRSVEGSCG
`
`F
`
`* pegylation sites
`* sites de pégylation
`* posiciónes de pegilación
`
`tetradecafluorohexane
`
`tétradécafluorohexane
`
`tetradecafluorohexano
`
`C6F14
`
`FF
`
`FF
`
`F3C
`
`CF3
`
`F F
`
`F F
`
`octafluoropropane
`
`octafluoropropane
`
`octafluoropropano
`
`C3F8
`
`F3C
`
`CF3
`
`F F
`
`pegvisomantum
`pegvisomant
`
`pegvisomant
`
`pegvisomant
`
`perflexanum
`perflexane
`
`perflexane
`
`perflexano
`
`perflutrenum
`perflutren
`
`perflutrène
`
`perflutreno
`
`200
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0018
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`pinokalantum
`pinokalant
`
`pinokalant
`
`pinokalant
`
`posaconazolum
`posaconazole
`
`posaconazole
`
`posaconazol
`
`(±)-3,4-dihydro-6,7-dimethoxy-a-phenyl-N,N-bis(2,3,4-
`trimethoxyphenethyl)-1-isoquinolineacetamide
`
`(2RS)-2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-1-yl)-2-phényl-
`N,N-bis[2-(2,3,4-triméthoxyphényl)éthyl]acétamide
`
`(±)-3,4-dihidro-6,7-dimetoxi-a-fenil-N,N-bis(2,3,4-trimetoxifenetil)-
`1-isoquinolinacetamida
`
`C41H48N2O9
`
`OCH3
`
`H3CO
`
`H
`
`N
`
`N
`
`O
`
`OCH3
`
`OCH3
`
`OCH3
`
`OCH3
`
`OCH3
`
`OCH3
`
`and enantiomer
`et énantiomère
`y enantiómero
`
`4-[p-[4-[p-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-
`1-ylmethyl)-3-furyl]methoxy]phenyl]-1-piperazinyl]phenyl]-1-[(1S,2S)-1-
`ethyl-2-hydroxypropyl]-D2-1,2,4-triazolin-5-one
`
`4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophényl)-5-(1H-1,2,4-triazol-1-ylméthyl)=
`tétrahydrofuran-3-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-2-[(1S,2S)-1-
`éthyl-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
`
`4-[p-[4-[p-[[(3R,5R)-5-(2,4-difluorofenil)tetrahidro-5-(1H-1,2,4-triazol-1-
`ilmetil)-3-furil]metoxi]fenil]-1-piperazinil]fenil]-1-[(1S,2S)-1-etil-2-
`hidroxipropil]-D2-1,2,4-triazolin-5-ona
`
`C37H42F2N8O4
`
`H3C
`H3C
`
`H
`
`O
`
`N
`
`N
`
`O H
`
`F
`
`F
`
`N
`
`N N
`
`O
`
`N
`
`N
`
`N
`
`201
`
`H OH
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0019
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`(S)-2,2-dimethyl-4-[[p-(4-pyridyloxy)phenyl]sulfonyl]-
`3-thiomorpholinecarbohydroxamio acid
`
`(3S)-N-hydroxy-2,2-diméthyl-4-[[4-(pyridin-4-yloxy)phényl]sulfonyl]=
`thiomorpholine-3-carboxamide
`
`ácido (S)-2,2-dimetil-4-[[p-(4-piridiloxi)fenil]sulfonil]-
`3-tiomorfolinacarbohidroxámico
`
`O
`
`N
`
`C18H21N3O5S2
`
`O
`
`OO
`
`S
`
`SN
`
`CH3
`
`NH
`
`H
`H3C
`
`HO
`
`(-)-p-[(4aR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-
`2-methylbenzo[c][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide
`
`(-)-4-[(4aR*,10bS*)-9-éthoxy-8-méthoxy-2-méthyl-1,2,3,4,4a,10b-
`hexahydrobenzo[c][1,6]naphtyridin-6-yl]-N,N-bis(1-méthyléthyl)benzamide
`
`(-)-p-[(4aR*,10bS*)-9-etoxi-1,2,3,4,4a,10b-hexahidro-8-metoxi-
`2-metilbenzo[c][1,6]naftiridina-6-il]-N,N-diisopropilbenzamida
`
`C29H39N3O3
`
`O
`
`CH3
`
`H3CO
`
`H
`
`N
`
`H
`
`CH3
`
`N
`
`or enantiomer
`ou énantiomère
`o enantiómero
`
`H3C
`
`CH3
`
`H3C
`
`N
`
`CH3 O
`
`(2S)-1-[[(2R,3S)-5-chloro-3-(o-chlorophenyl)-1-[(3,4-dimethoxyphenyl)=
`sulfonyl]-3-hydroxy-2-indolinyl]carbonyl]-2-pyrrolidinecarboxamide
`
`(2S)-1-[[(2R,3S)-5-chloro-3-(2-chlorophényl)-1-[(3,4-diméthoxyphényl)=
`sulfonyl]-3-hydroxy-2,3-dihydro-1H-indol-2-yl]carbonyl]pyrrolidine-
`2-carboxamide
`
`(2S)-1-[[(2R,3S)-5-cloro-3-(o-clorofenil)-1-[(3,4-dimetoxifenil)sulfonil]-
`3-hidroxi-2-indolinil]carbonil]-2-pirrolidinacarboxamida
`
`prinomastatum
`prinomastat
`
`prinomastat
`
`prinomastat
`
`pumafentrinum
`pumafentrine
`
`pumafentrine
`
`pumafentrina
`
`relcovaptanum
`relcovaptan
`
`relcovaptan
`
`relcovaptán
`
`202
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0020
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`C28H27Cl2N3O7S
`
`H3CO
`
`H3CO
`
`Cl
`
`O
`
`S
`N
`
`O
`
`O
`
`O
`
`H
`
`NH2
`
`N
`
`H
`OH
`Cl
`
`33-172-keratinocyte growth factor 2 (human)
`
`33-172-facteur 2 humain de croissance du kératinocyte
`
`33-172-factor 2 de crecimiento de queratinocitos (humano)
`
`C723H1131N209O204S5
`
`SYNHLQGDVR
`
`WRKLFSFTKY
`
`FLKIEKNGKV
`
`SGTKKENCPY
`
`SILEITSVEI
`
`GVVAVKAINS
`
`NYYLAMNKKG
`
`KLYGSKEFNN
`
`DCKLKERIEE
`
`NGYNTYASFN
`
`WQHNGRQMYV
`
`ALNGKGAPRR
`
`GQKTRRKNTS
`
`AHFLPMVVHS
`
`4-amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-c]quinoline-1-
`ethanol
`
`1-[4-amino-2-(éthoxyméthyl)-1H-imidazo[4,5-c]quinoléin-1-yl]-
`2-méthylpropan-2-ol
`
`4-amino-2-(etoximetil)-a,a-dimetil-1H-imidazo[4,5-c]quinolina-1-etanol
`
`C17H22N4O2
`
`CH3
`
`H3C OH
`
`CH3
`
`O
`
`NN
`
`N
`
`NH2
`
`repiferminum
`repifermin
`
`répifermine
`
`repifermina
`
`resiquimodum
`resiquimod
`
`résiquimod
`
`resiquimod
`
`risarestatum
`risarestat
`
`risarestat
`
`(±)-5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione
`
`(5RS)-5-[3-éthoxy-4-(pentyloxy)phényl]thiazolidine-2,4-dione
`
`203
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0021
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`risarestat
`
`(±)-5-[3-etoxi-4-(pentiloxi)fenil]-2,4-tiazolidinadiona
`
`C16H21NO4S
`
`H3C
`
`O
`
`9-nitrocamptothecin
`
`O
`
`S
`
`NH
`
`H
`
`O
`
`and enantiomer
`et énantiomère
`y enantiómero
`
`O
`
`CH3
`
`(4S)-4-éthyl-4-hydroxy-10-nitro-1,12-dihydro-14H-pyrano[3’,4’:6,7]=
`indolizino[1,2-b]quinoléine-3,14(4H)-dione
`
`9-nitrocamptotecina
`
`C20H15N3O6
`
`O2N
`
`O
`
`N
`
`O
`
`N
`
`HO
`
`O
`CH3
`
`N-[2-[4-[2-[(8-amino-7-chloro-1,4-benzodioxan-5-
`yl)carbonyl]ethyl]piperidino]ethyl]methanesulfonamide
`
`N-[2-[4-[3-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-
`3-oxopropyl]pipéridin-1-yl]éthyl]méthanesulfonamide
`
`N-[2-[4-[2-[(8-amino-7-cloro-1,4-benzodioxan-5-il)carbonil]etil]piperidino]=
`etil]metanosulfonamida
`
`HN
`
`S
`O O
`
`CH3
`
`C19H28ClN3O5S
`
`O
`
`H2N
`
`Cl
`
`O
`
`O
`
`N
`
`(S)-3-[(4’-chloro-4-biphenylyl)carbonyl]-2-[(phenylthio)methyl]propionic acid
`
`acide (2S)-4-(4’-chlorobiphényl-4-yl)-4-oxo-2-[(phénylsulfanyl)méthyl]=
`butanoïque
`
`rubitecanum
`rubitecan
`
`rubitécan
`
`rubitecán
`
`sulamserodum
`sulamserod
`
`sulamsérod
`
`sulamserod
`
`tanomastatum
`tanomastat
`
`tanomastat
`
`204
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0022
`
`

`

`WHO Drug Information, Vol. 14, No. 3, 2000
`
`RECOMMENDED INN: List 44
`
`tanomastat
`
`ácido (2S)-4-(4’-clorobifenil-4-il)-4-oxo-2-[(fenilsulfanilo)metil]butanoico
`
`C23H19ClO3S
`
`HO2C
`
`S
`
`H
`
`O
`
`Cl
`
`(+)-hydroxymethyl (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-
`[[1-(2-thiazolin-2-yl)-3-azetidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-
`carboxylate, 2-pivalate
`
`(+)-(4R,5S,6S)-3-[[1-(4,5-dihydrothiazol-2-yl)azétidin-3-yl]sulfanyl]-6-[(1R)-
`1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxy-
`late de [(2,2-diméthylpropanoyl)oxy]méthyle
`
`2-pivalato y (4R,5S,6S)-6-[(1R)-1-hidroxietil]-4-metil-7-oxo-3-[[1-(2-tiazolin-
`2-il)-3-azetidinil]tio]-1-azabiciclo[3.2.0]hept-2-eno-2-carboxilato de metileno
`
`C22H31N3O6S2
`
`O
`
`N
`
`O
`
`H3C
`
`HO
`
`H
`
`H H
`
`H CH3
`
`N
`
`O
`
`O
`
`H3C
`
`CH3
`
`CH3
`
`S
`
`O
`
`S
`
`N
`
`205
`
`[[(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid
`
`acide [[(1R)-2-(6-amino-9H-purin-9-yl)-1-
`méthyléthoxy]méthyl]phosphonique
`
`ácido [[(R)-2-(6-amino-9H-purin-9-il)-1-metiletoxi]metil]fosfónico
`
`O
`
`P
`
`OH
`OH
`
`O
`
`H
`CH3
`
`C9H14N5O4P
`
`NN
`
`NH2
`
`N
`
`N
`
`tebipenemum
`tebipenem
`
`tébipénem
`
`tebipenem
`
`tenofovirum
`tenofovir
`
`ténofovir
`
`tenofovir
`
`West-Ward Exhibit 1074
`Everolimus INN 2000
`Page 0023
`
`

`

`RECOMMENDED INN: List 44
`
`WHO Drug Information, Vol. 14, No. 3, 2000
`
`D-alanyl-L-lysyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-phenylalanyl-L-
`alanyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-
`threonyl-L-prolinamide
`
`D-alanyl-L-lysyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-phénylalanyl-L-
`alanyl-L-asparaginyl-L-isoleucyl-L-valyl-L-thréonyl-L-prolyl-L-arginyl-L-
`thréonyl-L-prolinamide
`
`D-alanil-L-lisil-L-prolil-L-valil-L-valil-L-histidil-L-leucil-L-fenilalanil-L-alanil-
`L-asparaginil-L-isoleucil-L-valil-L-treonil-L-prolil-L-arginil-L-treonil-L-prolinamida
`
`C87H143N25O20
`
`D-Ala
`
`Lys Pro Val Val His
`
`Leu Phe Ala Asn
`10
`
`Ile
`
`Val
`
`Thr
`
`Pro
`
`Arg
`
`Thr
`
`Pro NH2
`
`N-(carbamoylmethyl)-2-propylvaleramide
`
`N-(2-amino-2-oxoéthyl)-2-propylpentanamide
`
`N-(carbamoilmetil)-2-propilvaleramida
`
`C10H20N2O2
`
`NH2
`
`O
`
`N H
`
`O
`
`H3C
`
`H3C
`
`1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-
`4-ethoxyphenyl]sulfonyl]-4-ethylpiperazine
`
`2-[2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]phényl]-5-mét